Latest Mental Health News

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

Thrive Tribe Technologies (ASX:1TT) has landed a three-year exclusive distribution agreement with Canadian NATO-registered defence contractor Effective Acceleration Ventures (EAV) to roll out its WooBoard and REFFIND platforms across NATO military forces.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Redox Limited posted a strong FY26 with record revenue of $1.33 billion, a 19.2% jump in statutory net profit, and a 4% dividend increase, while announcing a board leadership transition.

TALi Digital Limited (ASX: TD1) posted a 416% jump in revenue for FY26 but also recorded a $2.2 million loss driven by a $1.3 million impairment of its YCDI! intangible assets. The company is pursuing growth through AI-focused acquisitions and a $3.3 million capital raise.

Future Generation Global's half-year profit fell sharply as its portfolio lagged global benchmarks, yet it boosted its fully franked interim dividend reflecting confidence in its income sustainability.

Carindale Property Trust (ASX: CDP) reported a robust 50.7% jump in net profit for FY26, boosted by a $25.6 million property revaluation gain, alongside an 8.8% rise in funds from operations and a 5% lift in distributions.

Supply Network Limited reported a 15.4% rise in FY2026 revenue to $403.7 million and a 19% jump in net profit to $47.6 million, underpinning a 44-cent fully franked final dividend. The company is advancing major branch expansions and IT upgrades to support its $50 million revenue growth target for FY2027.

Emyria has cleared a key operational hurdle by resolving Authorised Prescriber capacity constraints in Perth and Queensland, enabling a planned expansion of treatment days in Q4 2026 through the recruitment of 15 new therapists.